Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why $dcvax (#ForAllCancers) > targeted therapies
— Allen Turner (@AllenTurner206) March 16, 2023
Resistance mechanisms limits the success of precision medicine (e.g targeted therapies) in cancer
A new batch of DCVax-L (i.e second course) can be made upon recurrence. Tx targets not lost, as they are with targeted therapies pic.twitter.com/fUY81HNZC6
Impressive LCM strategy before initial approval! #dcvax $nwbo
— Allen Turner (@AllenTurner206) February 15, 2023
DCVax-L + Poly-ICLC. Est primary completion Jan 2024. Unpublished interim results: ~50% survival at >8 YEARS.
DCVax-L + PD-1. Est primary completion Aug 2024. Unpublished interim results: ~65% survival at >26 mos. pic.twitter.com/T0jAwH65Uo
Thank you @WHOSTP for bringing together the best and the brightest of the #braintumorcommunity to advance better outcomes for patients with #braincancer@meredith_buxton, @TCloughesy, @DrAlfredYung, @dfarons, @J_deGrootMD, @MichaelLimMD, and @TheLizArmy at the White House… pic.twitter.com/k78CVAGfsy
— Global Coalition for Adaptive Research (@GCAResearch) May 25, 2023
A light shining over our relentless pursuit of bringing #DCVAX across the finish line for #GBM and All Solid Tumors patients https://t.co/m7kN28e7Em
— Michael Bigger (@biggercapital) May 23, 2023
very sorry to see this. thoughts and prayers to the family.
Thank you very much Lykiri.
Thank You very much.
Yes GBM. Thank you. I understand. Not really the proper place for me to ask. Ive been around Nwbo for over 10 tears. Didn't mean to insult anyone.
A friend of ours had 8 hour surgery two days ago. He is taking part in a trial with imvax , does any one on the board have any knowledge of the trial.
We will be victorious in our pursuit to help #GBM patients then all solid tumors patients https://t.co/edD5UPIYVD
— Michael Bigger (@biggercapital) May 14, 2023
same capt. long ride
I don't I was hoping someone could apply Nwbo story to the twitter conversation on that tweet.
Judging by the time people are waiting for call backs on DCVax, $nwbo must be overwhelmed w requests now w Manu and global shipping.
— annie post (@apwriter) May 8, 2023
Adam, you may not know, because I fight for Nurown approval every day, that these years #DyingWaiting has left me a quadriplegic with a trach. It's very difficult for me mentally to debate with a clearly biased journalist.
— Shah Minokadeh, M.D. (@MinoShah) May 6, 2023
I will post this response, but I'm staring death in the… https://t.co/MLuF2R1p4D
Massive uptick in google searches for DCVAX trade name "Murcidencel" is journos preparing for a story. News. $nwbo pic.twitter.com/ki1N0oJFB3
— annie post (@apwriter) May 3, 2023
Combos addresses 3 out of the top five cancers. Keytruda alone does not. Lung. Prostate. Breast. $nwbo
— annie post (@apwriter) May 3, 2023
Imagine the squeeze when @CohenMilstein takes them off the field for this witness intimidation and retribution. Mega #Moass per Wes Christian $nwbo legal consultant. Talking about $nwbo? Before ($1.20) and after lawsuit (.49). Best news in 20 yrs. Judge isn't stupid. pic.twitter.com/9f2wNjpE1H
— annie post (@apwriter) April 28, 2023
They took the bait. Now @CohenMilstein can take them off the field for duration of trial for witness intimidation. A trap. $nwbo pic.twitter.com/abvlLeP4zi
— annie post (@apwriter) April 28, 2023
The SEC suggests that its Order Competition proposal could save retail investors $1.5B a year. We analyzed the data and determined that retail investors would actually lose $2.4B. See the full interview at https://t.co/ggPPoAnFqf pic.twitter.com/GIA1AB52gD
— Citadel Securities (@citsecurities) April 28, 2023
https://t.co/Sn9liYLIap So 50% survival at 8 years moves to 50% survival at 10 years. I wish I could have offered the latter to Judge Weeks 10 years ago, when he was diagnosed. $nwbo @alphavestcap
— alphavestcapital.com (@alphavestcap) April 27, 2023
Threats made to $nwbo CEO, @UCLANeurology Dr. Liau, a head of @NYASciences (AF barred there? interesting.) Per @joanlappin. She claimed AF threatened them in writing. She warned me, beware the RU mob. She died how? @FBILosAngeles @FBI @EDNYnews @CohenMilstein @DOJCrimDiv
— annie post (@apwriter) April 25, 2023
Hey @adamfeuerstein. The real journos at Stat News roll their eyes at you behind your back. I can only imagine how many, who were around on 5/10, are gleefully cashing in as whistleblowers in upcoming RICO. Esp women. $nwbo @statnews @DOJCrimDiv pic.twitter.com/mMxcjzJMi0
— annie post (@apwriter) April 25, 2023
Dr. Zavoico earned his BS in Biology from St. Lawrence University in Canton, NY, and a Ph.D. in Physiology from the University of Virginia, Charlottesville, VA. He completed post-doctoral fellowships in Pharmacology at the University of Connecticut Health Center in Farmington, CT, and Hematology at Brigham & Women’s Hospital and Harvard Medical School, Boston, MA. At Bristol-Myers Squibb, Dr. Zavoico was involved in drug discovery research in thrombosis and then cell therapy and complement therapeutics development at Alexion Pharmaceuticals and T Cell Sciences. For several years, Dr. Zavoico served as a consultant in competitive intelligence, regulatory affairs, and medical writing for the biotech and pharmaceutical industries, which included Pfizer and Boehringer-Ingelheim as clients. He then transitioned to become a sell-side equity analyst for Cantor-Fitzgerald, MLV & Co., JonesTrading, and B. Riley FBR. In over 15 years he covered a broad range of small-to-mid size biotech and biopharmaceutical companies engaged in developing drugs and/or cell therapies for cancer, autoimmune diseases and inflammation, neurological and cardiovascular disorders, rare diseases, and vaccines. In the past several years, Dr. Zavoico returned to work in the biotech industry in investor relations and corporate development to first assist Cue Biopharma and now Northwest Biotherapeutics in developing their cancer immunotherapies. Dr.Zavoico has authored more than 30 scientific papers and book chapters and was the recipient of a Financial Times/Starmine Analyst award for two years in a row. He has collaborated with the NY Academy of Sciences for over 30 years in planning and organizing symposia on multiple topics, including the annual Frontiers of Cancer Immunotherapy symposium.
Has there ever been more low-hanging RICO fruit as this? Complete w thug threats. @DOJCrimDiv what are you waiting for? They're just taunting you now. $nwbo @EDNYnews @FBILosAngeles @FBIWFO @NewYorkFBI pic.twitter.com/Un0dcMRpU2
— annie post (@apwriter) April 20, 2023
A $nwbo RICO charge by @DOJCrimDiv that restricts #citadel to "close only" positions guarantees @POTUS re-election. Proves our oversight institutions still work for citizens and their 401ks. $spy @CohenMilstein
— annie post (@apwriter) April 20, 2023
we should have paid for a commercial during the show
try calling les. maybe he can make you feel better